American Association for Cancer Research--99th Annual Meeting. Clinical and preclinical data on promising therapeutics.
Karger
Guy A
GA
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. guy.karger@thomsonreuters.com
Lee
Wai
W
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000922:Immunotoxins / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051058:Oncogene Protein v-akt / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011494:Protein Kinases / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D004791:Enzyme Inhibitors; D000922:Immunotoxins; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C068619:CDC7 protein, human; C546842:MTOR protein, human; D019859:Proto-Oncogene Proteins c-met; D051058:Oncogene Protein v-akt; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases